Latest Share Chat

REMOVE ADS

Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,851.50 0.00 (0.00%)

Bid:

1,802.00

Ask:

1,999.00

Spread: 197.00 (10.932%)

Market Cap: £74.25b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Director/PDMR Shareholding

19 Apr 2023 15:30

RNS Number : 8007W

GSK PLC

19 April 2023

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	456
			£15.2240	682
			£15.2240	1,133

d)	Aggregated information
d)	Aggregated volume Price	2,271 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	316
			£15.2240	471
			£15.2240	702

d)	Aggregated information
d)	Aggregated volume Price	1,489 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr H Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.3200	309
			$38.3200	233
			$38.3200	369

d)	Aggregated information
d)	Aggregated volume Price	911 $38.3200
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	66
			£15.2240	107
			£15.2240	206

d)	Aggregated information
d)	Aggregated volume Price	379 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	79
			£15.2240	131
			£15.2240	200

d)	Aggregated information
d)	Aggregated volume Price	410 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	40
			£15.2240	61
			£15.2240	124

d)	Aggregated information
d)	Aggregated volume Price	225 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	123
			£15.2240	224
			£15.2240	483

d)	Aggregated information
d)	Aggregated volume Price	830 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2023 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.3200	22
			$38.3200	97

d)	Aggregated information
	Aggregated volume Price	119 $38.3200
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	97
			£15.2240	148
			£15.2240	279

d)	Aggregated information
d)	Aggregated volume Price	524 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	73
			£15.2240	135
			£15.2240	224

d)	Aggregated information
d)	Aggregated volume Price	432 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	56
			£15.2240	93
			£15.2240	146

d)	Aggregated information
d)	Aggregated volume Price	295 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	116
			£15.2240	98
			£15.2240	357

d)	Aggregated information
d)	Aggregated volume Price	571 £15.2240
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr T Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	169

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Ms E Walmsley

Position/status

Chief Executive Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GSK plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period

Price(s) and volume(s)

Price(s)	Volume(s)
£15.2240	4,731.228

Aggregated information

Aggregated volume Price

N/A (single transaction)

Date of the transaction

2023-04-17

Place of the transaction

London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.2240	2,573.292

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2023
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$37.5050	4

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Vishal Sikka
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2023
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$37.5050	10

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-04-17
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFDFLUEDSEFL

Date		Source	Headline
1st Jun 2026	3:00 pm	RNS	Total Voting Rights
1st Jun 2026	3:00 pm	RNS	Transaction in Own Shares
28th May 2026	9:30 am	RNS	Positive Phase 3 data for bepirovirsen
27th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
26th May 2026	3:00 pm	RNS	Admission to Trading
26th May 2026	3:00 pm	RNS	Transaction in Own Shares
22nd May 2026	10:30 am	RNS	Q2 2026 Results Date Confirmed - 28 July 2026
20th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
19th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
18th May 2026	3:00 pm	RNS	Transaction in Own Shares
18th May 2026	7:00 am	RNS	Japan MHLW approves Arexvy for adults 18-49 AIR
14th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
11th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
11th May 2026	7:05 am	RNS	Collaboration with CTTQ for bepirovirsen
11th May 2026	7:00 am	RNS	GSK - final tranche of share buyback programme
6th May 2026	6:22 pm	RNS	Result of AGM
5th May 2026	3:30 pm	RNS	Director/PDMR Shareholding
1st May 2026	3:00 pm	RNS	Holding(s) in Company
1st May 2026	3:00 pm	RNS	Total Voting Rights
29th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
29th Apr 2026	7:00 am	RNS	1st Quarter Results
28th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
28th Apr 2026	7:00 am	RNS	Bepirovirsen priority review US filing acceptance
27th Apr 2026	12:00 pm	RNS	Efimosfermin granted US/EU regulatory designations
27th Apr 2026	7:00 am	RNS	TESARO update on AnaptysBio Inc. litigation
24th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
23rd Apr 2026	7:00 am	RNS	Transaction in Own Shares
22nd Apr 2026	7:00 am	RNS	Transaction in Own Shares
21st Apr 2026	7:00 am	RNS	Transaction in Own Shares
20th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
20th Apr 2026	7:00 am	RNS	Blenrep approved in China for 2L+ multiple myeloma
20th Apr 2026	7:00 am	RNS	Transaction in Own Shares
17th Apr 2026	7:00 am	RNS	Transaction in Own Shares
16th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
16th Apr 2026	7:00 am	RNS	Transaction in Own Shares
15th Apr 2026	7:12 am	RNS	GSK completes acquisition of 35Pharma Inc.
15th Apr 2026	7:00 am	RNS	Transaction in Own Shares
14th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
14th Apr 2026	7:00 am	RNS	Transaction in Own Shares
13th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
13th Apr 2026	7:00 am	RNS	Transaction in Own Shares
13th Apr 2026	7:00 am	RNS	GSK presents positive data for BEHOLD 1 B7 H4 ADC
10th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
10th Apr 2026	7:00 am	RNS	Transaction in Own Shares
9th Apr 2026	3:30 pm	RNS	Director/PDMR Shareholding
9th Apr 2026	7:00 am	RNS	Transaction in Own Shares
8th Apr 2026	7:00 am	RNS	Exdensur approved for CRSwNP in China
8th Apr 2026	7:00 am	RNS	Transaction in Own Shares
7th Apr 2026	7:00 am	RNS	Transaction in Own Shares
2nd Apr 2026	7:00 am	RNS	Transaction in Own Shares

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending